The purpose of this long-term study is to provide additional evidence of safety and efficacy
of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase
3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg
or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701.
Participants and investigators will be blinded to dose unless otherwise notified by the